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Available online 8 July 2014Abstract The heart has a limited capacity for regeneration following injury. Recent strategies to promote heart regeneration
have largely focused on autologous and allogeneic cell-based therapy, where the transplanted cells have been suggested to
secrete unknown paracrine factors that are envisioned to promote endogenous repair and/or mobilization of endogenous heart
progenitors. Here, we discuss the importance of paracrine mechanisms in facilitating replication of endogenous epicardial
progenitor cells in the adult heart and signaling their subsequent reactivation and de novo differentiation into functional cell
types such as endothelial cells and cardiomyocytes. Moreover, we discuss the use of a novel modified RNA technology in
delivering such therapeutic paracrine factors into myocardium following injury. These studies suggest that modified mRNA may
be a valuable experimental tool for the precise in vivo identification of paracrine factors and their downstream signaling that
may promote heart repair, cardiac muscle replication, and/or heart progenitor mobilization. In addition, these studies lay the
foundation for a new clinically tractable technology for a cell-free approach to promote heart regeneration.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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Currently, heart disease is the leading cause of mortality in the
industrialized world, partly due to the inability of the heart to
regenerate in adults; and also the dietary and life style changes
leading to amarked increase in the incidence of type II diabetes
(for review, see Armstrong et al., 2013; Carvalheira et al., 2013;
Ptaszek et al., 2012). Treatment options primarily address
symptomatic manifestations; and current therapeutics can only
delay the progression of heart failure until potential orthotopic
heart transplantation is available (Ptaszek et al., 2012).
Nevertheless, given the shortage of donor hearts for transplan-
tation, there is an urgent need for novel therapies to repair
severely diseased hearts. To address this issue, there is a
growing interest in three research areas for heart regeneration
including the use pluripotent stem cells (PSCs) for cell
replacement therapy (for a review, see Addis and Epstein,
2013; Lui et al., 2012; Matsa et al., 2014; Vunjak-Novakovic et
al., 2011; Xu et al., 2012), direct reprogramming of cardiac
fibroblasts into myocardium in vivo (Fu et al., 2013; Ieda et al.,
2010; Qian et al., 2012), or replication and reactivation of
endogenous quiescent cardiovascular progenitor cells for
differentiating into functional blood vessels and de novo cardiac
muscle (Chong et al., 2011; Smart et al., 2011; Zangi et al.,
2013). In this review, we focus on reactivation of our
endogenous regenerative capacity through paracrine mecha-
nisms, and describe a new technological platform via synthetic
modified mRNAs to express these factors in vivo in the heart
following myocardial infarction.Paracrine mechanisms: lessons from
cell-based therapies
Over the last decade, there has been a growing research
interest in cell-based therapies with the hope of improving
heart functions and attenuating adverse left ventricular (LV)
remodeling in both ischemic and non-ischemic cardiomyopathy.
Particularly, stem cells and progenitor cells which have the
potential to self-renew and differentiate into functional cardiac
muscle are attractive candidates for these purposes. The
concept of cell-based regeneration has proven successful in
clinical practice for over 50 years (Soiffer, 2008), in which
patients receive umbilical cord blood hematopoietic stem cells
which replenish their entire repertoire of immune cells
following bone marrow transplantation. To date, in cell-based
studies, skeletal myoblasts (Taylor et al., 1998), bone
marrow-derived mononuclear cells (Balsam et al., 2004; Murry
et al., 2004), bone marrow- (Silva et al., 2005) or adipose- (Cai
et al., 2009; Valina et al., 2007) derived mesenchymal stem
cells, CD34+ hematopoietic stem cells (Botta et al., 2004; Wang
et al., 2010), CD133+ endothelial progenitor cells (Stammet al.,
2007; Voo et al., 2008) and c-kit+ (Kajstura et al., 2005; Limana
et al., 2005) or Sca-1+ (Wang et al., 2006) cardiac progenitor
cells have been introduced into the damaged heart; however,
results from all these pre-clinical and clinical trials remain
ambiguous and therapies are yet to be proven conclusively
effective (for a review, see Sanganalmath and Bolli, 2013).While
transdifferentiation of non-cardiac cells into cardiomyocytes
and vascular cells following transplantation into the damaged
heart remains controversial (Balsam et al., 2004; Murry et al.,2004), recent studies have also challengedwhether adult cardiac
progenitor cells can robustly regenerate heart muscle in vivo in
both experimental model systems (van Berlo et al., 2014) and
clinical studies (Nowbar et al., 2014).
Recently, human embryonic stem cells (hESCs) or induced
pluripotent stem cells (hiPSCs), by virtue of their ability to
self-renew and differentiate into almost all cell types of the
body, have also been directed to differentiate into
cardiomyocytes for transplantation studies (Cai et al., 2007;
Caspi et al., 2007; Chong et al., 2014). Human ESC-derived
cardiomyocytes were shown to attenuate LV remodeling and
improve LV systolic function in rat hearts following myocardial
infarction (MI) (Cai et al., 2007; Caspi et al., 2007). More
recently, human ESC-derived cardiomyocytes were also dem-
onstrated to generate extensive vascularized cardiac muscle in
the infarcted hearts of non-human primates (Chong et al.,
2014). Despite the advantage of using hESCs or hiPSCs to
generate large numbers of human cardiomyocytes for clinical
transplantation, these cells were quite diverse in terms of
atrial/ventricular electrophysiological properties, as well
as being partially mature and, therefore, proarrhythmic
(Chong et al., 2014), resembling fetal-like rather than adult
cardiomyocytes (for a review, see Lui KO et al., 2013). In
addition, it is impossible to purify cardiomyocytes from human
pluripotent stem cell systems without genetic markers and
cardiomyocyte-specific cell surface markers that would allow
complete purification have not been identified. Moreover, the
success of cell-based therapies depends very much on the route
of delivery, dosage and frequency of cell administration, and
the degree of engraftment, long-term survival, lineage com-
mitment and integration with the host myocardium (for a
review, see Vunjak-Novakovic et al., 2011; Sanganalmath and
Bolli, 2013). The optimal protocol is yet to be determined to
gain the maximum benefits from transplanting each of the
different cell types into the damaged heart.
It has been proposed that the beneficial effects of cell-based
therapies might be mediated via several direct and indirect
mechanisms, including recruitment of endogenous progenitors,
differentiation into functional cardiomyocytes and vascular
cells, induction of angiogenesis, promotion of perfusion,
reduction of fibrosis and inhibition of apoptosis
(Vunjak-Novakovic et al., 2011; Sanganalmath and Bolli, 2013;
Loffredo et al., 2011). These repair processes are, in fact,
mediated by proteins and small molecules and, therefore,
replenishing the damaged heart with therapeutic paracrine
factors in vivo may be sufficient to directly activate repair
mechanisms, opening a new avenue to regenerative medicine
without cellular transplantation (for a review, see Green and
Lee, 2013). To search for these therapeutic paracrine factors,
we can learn from the ischemic heart which secretes “Mayday”
signals (e.g. stromal cell-derived factor-1) for recruiting
progenitor cells that express the homing receptor (e.g. CXCR4)
and home to the peri-infarct zone (Segers et al., 2007); or from
studies using heterochronic parabiosis, a surgical technique in
which joining of two mice leads to a shared circulation, that
identified rejuvenative circulating factors (e.g. growth differ-
entiation factor 11) secreted by the young, healthy mice which
could improve cardiac function in old mice with age-related
cardiac hypertrophy (Loffredo et al., 2013). Moreover, we may
also learn from a growing human fetal heart to identify
paracrine factors (e.g. vascular endothelial growth factor,
VEGF) responsible for proliferation of endogenous cardiac
695Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNAprogenitor cells (Lui et al., 2013; Qyang et al., 2007) and their
subsequent differentiation into different cellular lineages of the
heart, namely cardiomyocytes, and smooth muscle and endo-
thelial cells.
Lineage-mapping studies: searching for
therapeutic paracrine factors
during cardiogenesis
Over the past four decades, hematopoietic growth factors such
as granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF) and erythro-
poietin (EPO) (Nemir et al., 2012) have been commercially
available for clinical use to treat granulocytopenias, anemia,
and neutropenia in patients with malignancies or congenital
bone marrow failure (Groopman et al., 1989; Vose and
Armitage, 1995). Indeed, there is a tightly-regulated network
of hematopoietic growth factors or cytokines secreted by
immune cells, including G-CSF, M-CSF, GM-CSF, EPO, stem-cell
factor (SCF), interleukins, interferons and tumor necrosis
factor. These paracrine factors are involved in self-renewal,
mobilization and differentiation of hematopoietic stem cells,
and inmaturation and activation of their differentiatedmyeloid
or lymphoid cells to maintain proper functions of the immune
system.
Similar to hematopoietic stem cells, multipotent cardiovas-
cular progenitor cells are also capable of differentiating into
different cellular lineages of the heart such as cardiomyocytes,
pacemaker cells, smooth muscle cells and endothelial cells
during mammalian cardiogenesis. Recent advances in the cre/
lox technology enable us to identify distinct cardiovascular
progenitor cells and label their derivatives in murine lineage-
tracing models. The heart develops from defined multipotent
cardiovascular progenitor cells located at the first heart field
marked by expression of Tbx5 and Nkx2.5 (Herrmann et al.,
2011); the second heart field marked by expression of Isl1
(Qyang et al., 2007; Laugwitz et al., 2005; Moretti et al., 2006);
and the epicardium and epicardium-derived progenitor cells
(EPDCs) are marked by expression of WT1 (Smart et al., 2011;
Zangi et al., 2013; Zhou et al., 2008) (Fig. 1). These progenitors
are capable of differentiating into the three major cellular
lineages of the heart including cardiomyocytes, and smooth
muscle and endothelial cells as demonstrated by lineage-
tracing experiments. Despite the discovery of thesemultipotent
cardiovascular progenitor cells, which are capable of further
differentiating into mature cardiac muscle with intact calcium
dynamics and action potentials (Laugwitz et al., 2005), clinical
application of the embryonic Tbx5+, Nkx2.5+ or Isl1+ cardiovas-
cular progenitor cells for autologous cell-based therapy is
limited by their absence in the adult heart. In the normal adult
heart, there is an endogenous pool of WT1+ EPDCs, albeit the
numbers are very low (Smart et al., 2011; Zangi et al., 2013;
Zhou et al., 2011). The WT1+ EPDCs readily differentiate into
cardiac fibroblasts and smooth muscle cells, but have limited
capacity to form endothelial cells, and make little, if any,
contribution to cardiomyocytes in both the normal and
infarcted adult hearts (Smart et al., 2011; Zangi et al., 2013;
Zhou et al., 2011). Additional factors such as thymosin beta-4
(Smart et al., 2011) and VEGFA (Zangi et al., 2013) have been
used to amplify the endogenous WT1+ EPDCs and activate their
cardiac differentiation potential following MI.In addition to EPDCs, endogenous c-kit+ cells have been
reported as cardiovascular progenitor cells capable of generat-
ing the three major cellular lineages of the heart (Beltrami et
al., 2003; Ellison et al., 2013). Since the c-kit+ cardiovascular
progenitor cells can be purified by flow cytometry and are
present in both adult and infarcted hearts, various clinical trials
have been conducted to investigate their potential in treating
damaged tissues after MI (Sanganalmath and Bolli, 2013; Bolli et
al., 2011; Chugh et al., 2012); however, the cardiac differen-
tiation potential of the c-kit+ cells has been recently challenged
by new findings derived from a murine lineage-tracing study
(van Berlo et al., 2014). Molkentin and colleagues generated
two reporter systems where Cre or a tamoxifen-inducible
MerCreMer proteinwas targeted to the Kit locus to permanently
mark and trace the cell-fate of c-kit+ cells (van Berlo et al.,
2014). In contrary to previous reports which suggested the
cardiac differentiation potential of c-kit+ cells (Beltrami et al.,
2003; Ellison et al., 2013), Molkentin and colleagues have
demonstrated that the endogenous c-kit cells in the heart,
while readily able to generate cardiac endothelium, rarely
(0.027%) contributed to cardiomyocytes (van Berlo et al., 2014).
Moreover, their contribution in cardiac repair as reported in
recent clinical trials has also been challenged (Nowbar et al.,
2014). Therefore, more lineage-mapping studies and careful
interpretation are required to determine, unequivocally, the
cardiac differentiation potential of the c-kit+ cells following MI
particularly in both preclinical and clinical settings. Altogether,
these studies will be important to verify the therapeutic
potential of the c-kit+ cells for autologous cell-based therapy,
and provide new insights into regenerative cardiovascular
therapeutics.
During normal aging or following myocardial injuries such as
MI, replacement of cardiomyocytes occurs at a very low rate
and is mediated by de novo differentiation of endogenous
cardiovascular progenitor cells (Smart et al., 2011; Zangi et al.,
2013; Zhou et al., 2008; Hsieh et al., 2007), and is in contrast to
the replication of pre-existing cardiomyocytes seen in rodent
models which occurs in the first few days of life (P1–P4) (Li et
al., 1996; Porrello et al., 2011; Naqvi et al., 2014) or during
adolescence (P14–18) (Naqvi et al., 2014) driven by thyroid
hormone (T3). Cardiosphere-forming cells (CDCs), found in
human percutaneous endomyocardial biopsies, are capable of
differentiating into cardiomyocytes (Smith et al., 2007); and
adoptive transfer of cardiosphere-derived cells (CDCs), expand-
ed in vitro, into human infarcted hearts during a recent
randomized phase-I clinical trial led to reduced scar size,
increased viablemyocardiumand improved regional LV function
(Makkar et al., 2012; Malliaras et al., 2014a). While the
cardiovascular progenitor cells might harness great potential
for autologous cell-based therapy, the molecular pathways that
underpin development of various multipotent cardiovascular
progenitor cells are still unclear. Gaps in our understanding of
paracrine signaling responsible for expansion of cardiovascular
progenitor cells in vivo and subsequently for making their
cell-fate decisions have presented substantial barriers to heart
regeneration. Since one of the major mechanisms by which
transplanted cells (e.g. CDCs) function is through paracrine
signaling (e.g. VEGF (Chimenti et al., 2010), hepatocyte growth
factor/HGF (Chimenti et al., 2010), insulin-like growth factor-
1/IGF-1 (Chimenti et al., 2010) and stromal cell-derived factor
1/SDF-1 (Malliaras et al., 2014b)), targeting expansion and
myocardial differentiation of cardiovascular progenitor cells
Figure 1 A cellular hierarchy of heart cell lineage diversification from embryonic and adult multipotent cardiovascular progenitors.
This provisional schematic fate map of cardiac progenitors is based on currently available data from mouse and human ES cells with in
vivo lineage-tracing results. The self-renewing, multipotent cardiovascular progenitors derived from both embryonic first (FHF,
marked by Nkx2.5) and second (SHF, marked by Isl1) heart field and adult epicardium (EP, marked by WT1) can give rise to the
self-renewing, committed vascular and myocardial progenitors. The committed vascular progenitors further differentiate into
CD144+CD31+ endothelial cells; whereas the committed myocardial progenitors differentiate into cTnT+, Tnnt2+ and Tnni3+
cardiomyocytes. It is still unclear whether there is a defined population of committed smooth muscle progenitors or whether the
vascular SMMHC+ smooth muscle cells are differentiated from the vascular or myocardial progenitors.
696 K.O. Lui et al.once we understand the underlying signaling mechanism might
provide an alternative strategy for promoting heart
regeneration.
The paracrine hypothesis for cell-based therapy is the
concept that transplanted cells induce myocardial repair by
releasing signals (e.g. cytokines, chemokines, growth factors,
possibly exosomes and microparticles) into the injured myocar-
dium, which, in turn, promote a number of repair processes
including replication and activation of endogenous progenitor
cells, neovascularization, inhibition of apoptosis, inhibition of
hypertrophy, and favorable alterations of extracellularmatrices
(for a review, see Vunjak-Novakovic et al., 2011; Sanganalmath
and Bolli, 2013). Collectively, these actions result in enhanced
LV function, improved perfusion, reduced fibrosis and myocar-
dial repair (Gnecchi et al., 2008).VEGF165: one of the many paracrine factors
and signaling molecules that drives cell-fate
specification of cardiovascular progenitor cells
Our group has utilized human fetal hearts and a lineage-tracing,
Isl1–cre knock-in hESC line as tools to study the developmental
programs during human cardiogenesis and to examine theparacrine signaling mechanisms involved in self-renewal (Qyang
et al., 2007) and lineage specification (Lui et al., 2013; Bu et al.,
2009) of Isl1-expressing human cardiovascular progenitor cells.
We have reported previously that Wnt/beta-catenin signaling is
a major component by which cardiac mesenchymal cells
modulate self-renewal and inhibit differentiation of Isl1-
expressing cardiovascular progenitor cells isolated from
human fetal hearts (Qyang et al., 2007). Moreover, Isl1-
expressing cardiovascular progenitor cells derived from hESCs
are capable of differentiating into cardiomyocytes and smooth
muscle cells without added paracrine signaling (Lui et al., 2013;
Bu et al., 2009), albeit with low efficiency.
Paracrine signaling is required to drive vascular endothelial
cell specification of Isl1-expressing cardiovascular progenitor
cells. In order to identify paracrine signals responsible for
driving vascular cell-fate, we have performed quantitative gene
expression profiling and identified VEGF165 as the most
abundantly expressed paracrine factor in human fetal heart
vessels comparedwith non-cardiac, human umbilical cord blood
vessels (Lui et al., 2013). Replication of the human cardiovas-
cular progenitor cells is observed when cultured in the presence
of VEGF165 (Lui et al., 2013). In addition, VEGF165 alone is
sufficient to drive vascular specification of the Isl1-expressing
human cardiovascular progenitor cells away from cardiomyo-
cyte or smooth muscle cell fate. These Isl1 lineage-derived
697Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNAendothelial cells resemble Isl1-expressing endothelial interme-
diates located at the outflow tract of early human fetal hearts,
characterized by coexpression of Isl1 and vascular markers
including CD144 and vWF.
By recapitulating the developmental and/or therapeutic
role of paracrine factors in the clinic, one might be able to
bypass cell therapy by introducing therapeutic paracrine
factors directly into the ischemic heart. Indeed, various
growth factors have been investigated in clinical trials for
their potential in myocardial repair (Table 1), which fall into
several functional categories, including those involved in
promotion of angiogenesis (e.g. EPO (Silverberg et al., 2001)),
fibroblast growth factor 2/FGF2 (Simons et al., 2002) and
VEGF (Gao et al., 2010; Henry et al., 2003)); induction of
mobilization and activation of the endogenous, quiescent
progenitor cells (e.g. G-CSF (Abdel-Latif et al., 2008));
inhibition of apoptosis (e.g. EPO (Silverberg et al., 2001)),
FGF2 (Simons et al., 2002) and VEGF (Gao et al., 2010; Henry
et al., 2003)) and promotion of cardiomyocyte replication
(e.g. growth hormone (Tritos and Danias, 2008) and
neuregulin-1 (Jabbour et al., 2011)). Although these trials
have given novel insights into development of regenerative
therapeutics, it is still unclear whether these paracrine factors
can provide a long-term benefit to patients following such
treatments. In general, there is a lack of statistically
significant difference in functional outcomes (e.g. improve-
ment in myocardial perfusion or increase in left ventricularTable 1 Summary of paracrine factors used in clinical trials for
Factor Phase Patient type and no. Result
rhEPO Randomized,
controlled
trials
Chronic heart failure,
n = 32
An inc
in LVE
groups
rhFGF2 Phases I and II Coronary artery disease,
n = 337
No imp
myoca
reduct
but no
placeb
rhG-CSF Randomized,
controlled
trials
Acute MI, n = 385 Increa
(4.65%
EF b 5
that of
rhGrowth
hormone
A mixture of
controlled and
uncontrolled
trials
Congestive heart
failure,
n = 212 in 14 studies
Improv
the co
mass a
There
of arrh
rhNeuregulin-1 Phase I Chronic heart failure,
n = 15
Increa
12–84
compa
were r
Phase II Chronic heart failure,
n = 44
No stat
LVEF c
rhVEGF Phase I
(VIVA trial)
Coronary artery disease,
n = 178
Low-do
by day
improv
compa
Phase I Coronary artery disease,
n = 14
Improv
dose-d
Abbreviations — rh: recombinant human protein; LVEF: left ventriculaejection fraction/LVEF) in the treatment groups compared to
the placebo groups; and a lack of consistency between
repeated trials using the same paracrine factors.
There are possible complications associated with para-
crine factor-based therapy such as the limited half-life and
systemic release of the introduced proteins, desensitization
of the responding cells, and impaired capability of the failing
heart to reawaken endogenous regenerative mechanisms. In
short, given that many of the paracrine signaling systems
operate on multiple cell types of the heart, it is important to
note that therapeutic paracrine signaling should be localized
to stimulate only the target cells. Moreover, prolonged
expression might likely lead to unwanted side effects;
therefore, more studies are required to determine delivery
methodologies with the appropriate duration of expression.
It is also important to examine the effects of paracrine
factors in aged recipients with more severely damaged
myocardium, or even in a diabetic background which is also
clinically relevant.Modified VEGF165 mRNA: a delivery platform for
therapeutic paracrine factors in vivo
Indeed, various phase-I/II clinical trials with VEGF165/121 for
promoting revascularization in the ischemic heart have been
conducted by intracoronary, intravenous or intramyocardialmyocardial repair.
s Ref
rease of 5.5% and a decrease of 5.4%
F in the treatment and control
, respectively.
Silverberg et al. (2001)
rovement in exercise tolerance or
rdial perfusion at day 180. Significant
ion in angina was observed at day 90
t at day 180 compared to that of the
o group.
Simons et al. (2002)
sed EF in patients with early MI
, p b 0.0001) or with mean baseline
0% (4.73%, p b 0.0001) compared to
the controls.
Abdel-Latif et al. (2008)
ed LVEF by 4.3% compared to that of
ntrols. An increase in left ventricular
nd wall thickness was observed.
was no examination in development
ythmias.
Tritos and Danias (2008)
sed LVEF (4–12%, p b 0.001) at day
post infusion with neuregulin-1
red to controls. Adverse side effects
eported.
Jabbour et al. (2011)
istically significant difference in %
ompared to that of the placebo group.
Gao et al. (2010)
se rhVEGF did not have any effect
60 after infusion; high-dose rhVEGF
ed angina by day 120
red to that of the placebo group.
Henry et al. (2003)
ed myocardial perfusion at rest in a
ependent manner.
Braitsch et al. (2013)
r ejection fraction.
698 K.O. Lui et al.injection of recombinant protein (Henry et al., 2003; Hendel
et al., 2000; Sato et al., 2001), naked cDNA (Losordo et al.,
1998; Stewart et al., 2009), non-viral plasmid (Losordo et
al., 1998; Stewart et al., 2009) or adenoviral plasmid
(Hedman et al., 2003; Stewart et al., 2006); however, the
improvement in myocardial perfusion and LV function was
inconsistent between these trials (Table 2, for a review, also
see Hinkel et al., 2011; Formiga et al., 2012; Simon-Yarza et
al., 2012). The failure in achieving consistency in the
recombinant VEGF165 protein trials could be attributed to
the very short half-life of VEGF in plasma (about 30 min in
humans) (Carmeliet et al., 1999), a lack of controlled
release, and off-target side effects associated with systemic
delivery. The studies highlight the difficulty in achieving a
therapeutically relevant and durable dose for a lasting effect
in revascularization using recombinant VEGF165 protein.
Recently, biodegradable scaffolds including hydrogel (Gao et
al., 2011), collagen (Wu et al., 2011) or self-assembling
peptide nanofibers (NF) (Lin et al., 2012) have been implanted
to increase the retention of VEGF in the infarcted heart and
the use of NF could even prolong the release of VEGF for up to
14 days (Lin et al., 2012). Indeed, injection of the VEGF
protein with these biodegradable scaffolds shows better
improvement in vascularization and LV function following MI
(Gao et al., 2011; Wu et al., 2011; Lin et al., 2012). More
studies are still required to determine the risk of immune
rejection, fibrosis, formation of leaky blood vessels and edema
following the implantation.
Although the concept of direct interference with the
genetic and molecular foundation of cardiac cells is simple
and elegant, myocardial gene transfer is difficult to achieve
as a clinical reality. While the use of certain vectors ensures
durable release of VEGF without genome integration, these
approaches are limited by low gene transfer efficiency
(Hinkel et al., 2011). Improved VEGF165 expression with
adenoviral vectors leads to more robust neovascularization;
but also contributes to untoward effects, including potential
genomic integration, systemic inflammation against the viral
vectors (Wright et al., 2001), local edema (Rutanen et al.,
2004) or angiomas (Schwarz et al., 2000) as a result of
prolonged exposure to VEGF165. These side effects might
have masked the therapeutic benefit induced by VEGF165.
Therefore, better delivery technologies with more regulated
spatial and temporal expression of therapeutic gene prod-
ucts are needed.
To address issues associated with non-viral and viral
plasmid-mediated gene therapies, we (Zangi et al., 2013; Lui
et al., 2013) and others (Kariko et al., 2005, 2011; Kormann et
al., 2011; Mandal and Rossi, 2013; Warren et al., 2010) have
utilized modified mRNAs (modRNAs) as a non-immunogenic
tool to deliver proteins of interest into mammalian cells with
high efficiency. Since the immune system has a crucial role in
guarding against infections by detecting microbial metabo-
lism, both DNA and RNA can activate dendritic cells of the
innate immunity through recognition by Toll-like receptors
(TLRs). In translational studies, nucleoside modifications are,
therefore, needed to ensure escape from immune surveil-
lance. It has been reported that replacement of cytidine with
5-methyl-cytidine and uridine with pseudouridine suppresses
RNA recognition by dendritic cells via TLRs 3, 7 and 8 (Fig. 2)
(Kariko et al., 2005). Therefore, incorporation of modRNA
both reduces innate immune activation and increasesefficiency for mRNA translation (Kariko et al., 2011) (Fig. 2).
Recently, it has been demonstrated that twice weekly
application with an aerosol containing surfactant protein B
(SP-B) in the form of modRNA restored 71% expression of the
wildtype SP-B protein in vivo and prolonged survival of mice
with a lethal congenital lung disease attributed to SP-B
deficiency (Kormann et al., 2011). In addition to the added
stability of modRNAs compared to mRNAs, the non-integrating
nature ofmodRNAs also allows transient expression of proteins
which, if prolonged,might generate side effects. For instance,
high doses of VEGF165 can lead to formation of leaky blood
vessels (vascular hyperpermeability) (Nagy et al., 2012) and
hypotension (excessive release of nitric oxide) (Yang et al.,
2002); therefore, the use of VEGF modRNA could be safer than
the use of integrating vectors.
The identification of VEGF165 as a cell-fate switch in
determining vascular specification of the human Isl1-expressing
cardiovascular progenitors has led to pioneering work in using
VEGF165 modRNA as a therapeutic paracrine factor for driving
heart regeneration (Zangi et al., 2013; Lui et al., 2013). Direct
injection of a single paracrine factor such as VEGF165 in the form
of modRNAs not only leads to replication and reactivation of the
endogenous, quiescent WT1+ adult epicardial cells in the
infarcted myocardium, but also directs differentiation of these
cells away from a fibroblastic, scar-forming cell fate (Zhou et al.,
2008) and toward vascular andmyocardial cell fates (Zangi et al.,
2013) (Fig. 3). Such an approach stimulates the endogenous
regenerative capacity of an infarcted adult heart by limiting
pathological remodeling, effecting a significant improvement in
heart function including increased ejection fraction, reduced
fibrosis and prolonged survival (Zangi et al., 2013). Nevertheless,
future studies are still needed to determine whether the
modRNA technology is a safer and more efficacious approach
compared to other systems previously employed in pre-clinical
and clinical studies for delivering paracrine factors and signaling
molecules.Future perspectives
The emerging approaches that utilize synthetic, chemically
modified mRNA as paracrine factor therapeutics for regen-
erative cardiology could also be a paradigm for regeneration
in other tissues and organs. Indeed, in addition to the heart
(Zangi et al., 2013; Zhou et al., 2011), it has also been shown
that vascular endothelium-derived paracrine factors play an
important role in regeneration of liver (Ding et al., 2010),
lung (Ding et al., 2011) and pancreas (Brissova et al., 2014):
In the liver, liver sinusoidal endothelial cells secrete HGF
and Wnt2 which initiate hepatocyte replication and sustain
liver regeneration following 70% of partial hepatectomy
(Ding et al., 2010); in the lungs, pulmonary capillary
endothelial cells secrete VEGF, fibroblast growth factor
(FGF) and matrix metalloproteinase (MMP) 14 that induce
replication of epithelial progenitor cells for alveologenesis
following unilateral pneumonectomy (Ding et al., 2011); in the
pancreas, increased VEGF-A secretion in beta cells induces an
initial beta cell loss but subsequent beta cell replication
(Brissova et al., 2014). Therefore, the in vivo expression of
libraries of paracrine factors in the form of modRNA could
be informative for identifying known and unknown para-
crine factors for a diverse group of solid organ degenerative
Table 2 Summary of methodologies for VEGF delivery in myocardial repair.
Nature Format Route Preclinical or
clinical?
Strength Weakness Ref
Protein Recombinant
protein
Intracoronary Phase I
and II trials
Safe; local delivery; perfusion
improvement at high doses
Short-lived; single dose; lack
of controlled release
Henry et al. (2003) and
Hendel et al. (2000)
Recombinant
protein
Intravenous Phase I
and II trials
Safe Short-lived; off-target side
effects; no improvement in
perfusion
Henry et al. (2003) and
Sato et al. (2001)
Recombinant
protein
with hydrogel
Intramyocardial Preclinical
studies
Biodegradable; increased retention
of cells and proteins; increased
angiogenesis; improved LV functions
Immunogenic; side effects such
as fibrosis, leaky vessels or
edema were not determined
Gao et al. (2011)
Recombinant
protein with
collagen patch
Intramyocardial Preclinical
studies
Biodegradable; increased retention
of cells and proteins; increased
angiogenesis; improved LV functions
Immunogenic; side effects such
as fibrosis, leaky vessels or
edema were not determined
Wu et al. (2011)
Recombinant
protein with
nanofibers
Intramyocardial Preclinical
studies
Biodegradable; increased retention of
cells and proteins; prolonged release
up to 14 days; increased angiogenesis;
improved LV functions
Immunogenic; risk of fibrosis Lin et al. (2012)
DNA Naked cDNA or
non-viral plasmids
Intramyocardial Phase I
and II trials
Low cost; durable expression;
non-integrating
Lack of controlled release;
immunogenic; inconsistent
results from improvement in
angiogenesis or LV functions
Losordo et al. (1998) and
Stewart et al. (2009)
Viral plasmids
(adeno-associated
or lentiviral)
Intramyocardial Phase I
and II trials
Long-term expression; high transduction
efficiency; tissue-specific
Lack of controlled release;
random genome integration;
immunogenic/presence of
neutralizing antibodies;
inconsistent results from
improvement in angiogenesis
or LV functions
Hedman et al. (2003) and
Stewart et al. (2006)
RNA modRNA Intramyocardial Preclinical
studies
Non-integrating; non-immunogenic;
more stable; localized; highly efficient;
controlled release; progenitors activation;
increased angiogenesis; improved LV
functions
Cost; short-term expression Zangi et al. (2013)
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Figure 2 Modification of mRNA bypasses Toll-like receptor-induced apoptosis of transfected cells. (A) The exogenous mRNA that
enters the endosome of the transfected cell can be recognized by Toll-like receptors 7 and 8 (TLRs 7 & 8). TLR recognition induces
expression of genes involved in innate immunity such as type I interferons and RIG1, leading to a translational shutdown of proteins
and apoptosis of the transfected cells. (B). A change in two ribonucleotides of mRNA (uridine replaced by pseudouridine and cytidine
replaced by 5-methyl-cytidine) leads to a change in the secondary structure of mRNA, bypassing immune recognition through TLRs.
The modified mRNA goes to the ribosomes and can be translated to proteins without eliciting immune response or compromising the
genome of the transfected cells.
700 K.O. Lui et al.diseases. Specifically, promoting angiogenesis and revascu-
larization via VEGF modRNA, and in addition other angio-
genic paracrine factors, could also be an effective tool in
enhancing regeneration in multiple organ systems following
injuries.
Since the first and second heart field-derived cardiovascular
progenitor cells do not exist in the adult heart, either under
normal conditions or after MI (Sanganalmath and Bolli, 2013), it
is unlikely that they could be expanded following myocardial
injuries. It has been reported that several populations of
cardiovascular progenitor cells exist in the adult epicardium,
including WT1+ (Smart et al., 2011; Zangi et al., 2013; Zhou et
al., 2008), Tbx18+ (Zhou et al., 2011; Cai et al., 2008) or Tcf21+
(Braitsch et al., 2013) EPDCs, which contribute to scar
formation and fibrosis following MI. Nevertheless, it is still not
clear how to expand these endogenous quiescent progenitor
cells and inhibit them from differentiating into cardiacfibroblasts. Therefore, harnessing paracrine signaling with the
appropriate in vivo delivery strategy such as modRNAs might
stimulate replication and differentiation of EPDCs into more
functional cell types such as endothelial cells and
cardiomyocytes for heart regeneration.References
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